- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02677324
Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia
Phase II Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia
Study Overview
Detailed Description
This research study is a Phase II clinical trial. ABT-199 is a pill that blocks BCL-2, a protein that is important for the survival of WM cells.
The purpose of this research study is to evaluate how well the study drug works and the safety of ABT-199 as a single agent in participants with WM that has come back or has shown no response to previous treatment.
The FDA (the U.S. Food and Drug Administration) has not approved ABT-199 as a treatment for any disease.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- City of Hope National Medical Center
-
Palo Alto, California, United States, 94304
- Stanford University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Institute
-
-
New York
-
New York, New York, United States, 10065
- Weill Cornell Medical College
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinicopathological diagnosis of Waldenstrom's Macroglobulinemia and meeting criteria for treatment using consensus panel criteria from the Second International Workshop on Waldenstrom's macroglobulinemia (Owen 2003; Kyle 2003).
- Measurable disease, defined as presence of serum immunoglobulin M (IgM) with a minimum IgM level of > 2 times the upper limit of normal of each institution is required.
- Have received at least one prior therapy for WM.
- Age ≥ 18 years.
- ECOG performance status <2 (see Appendix A).
Participants must have normal organ and marrow function (growth factors cannot be given prophylactically to establish eligibility) as defined below:
- Absolute neutrophil count > 1,000/mm3
- Platelets > 50,000/mm3
- Hemoglobin > 8 g/dL
- Total bilirubin ≤ 1.5 mg/dL or < 2 mg/dL if attributable to hepatic infiltration by neoplastic disease
- AST (SGOT) and ALT (SGPT) < 2.5X the institutional upper limit of normal
- Creatinine clearance ≥50 ml/min
- Not on any active therapy for other malignancies with the exception of topical therapies for basal cell or squamous cell cancers of the skin.
- Females of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or have or will have complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) while participating in the study; and 2) for at least 28 days after discontinuation from the study. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. FCBP must be referred to a qualified provider of contraceptive methods if needed.
- Able to adhere to the study visit schedule and other protocol requirements.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Any serious medical condition, laboratory abnormality, uncontrolled intercurrent illness, or psychiatric illness/social condition that would prevent the participant from signing the informed consent form.
- Concurrent use of any other anti-cancer agents or treatments or any other study agents.
- Prior exposure to ABT-199 or BCL2 inhibitors.
- Prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, ECG finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the patient, including symptomatic hyperviscosity; alter the absorption, distribution, metabolism or excretion of ABT-199; or impair the assessment of study results.
- Grade > 2 toxicity (other than alopecia) continuing from prior anti-cancer therapy.
- Known CNS lymphoma.
- Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening.
- New York Heart Association classification III or IV heart failure.
- Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.
- Known history of Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), and/or Hepatitis C Virus (HCV) infection.
- Lactating or pregnant women.
- Inability to swallow tablets.
- History of non-compliance to medical regimens.
- Unwilling or unable to comply with the protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ABT199
ABT199 will be administered daily, with 28 consecutive days defined as a treatment cycle for a maximum for 26 cycles
|
Oral BCL-2 antagonist
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate
Time Frame: 2 years
|
Overall Response Rate= Minor response (>25%-50% reduction in serum IgM from baseline) + Partial Response (>50-90% reduction in serum IgM from baseline) + Very Good Partial Response (>90% reduction in serum IgM from baseline) + Complete Response (resolution of all symptoms, normalization of serum IgM with disappearance of IgM paraprotein, resolution of any adenopathy or splenomegaly).
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Complete Response
Time Frame: 2 years
|
A complete response is defined as having resolution of WM related symptoms, normalization of serum IgM levels with complete disappearance of IgM paraprotein by immunofixation, and resolution of any adenopathy or splenomegaly.
|
2 years
|
Number of Participants With Partial Response
Time Frame: 2 years
|
Partial response (PR) is defined as achieving a ≥50% reduction in serum IgM levels.
|
2 years
|
Number of Participants With Very Good Partial Response
Time Frame: 2 years
|
Very Good Partial Response (VGPR): is defined as ≥90% reduction in serum IgM levels, or normalization of serum IgM levels.
|
2 years
|
Number of Participants With Minor Response
Time Frame: 2 years
|
Minor Response (MR): A minor response (MR) is defined 25-49% reduction in serum IgM levels.
|
2 years
|
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0
Time Frame: 2 years
|
Number of participants who experienced an adverse event while on ABT-199
|
2 years
|
Number of Participants With Stable Disease
Time Frame: 2 years
|
Stable disease is defined as having <25% increase in serum IgM levels and <25% reduction in serum IgM levels
|
2 years
|
Progression Free Survival
Time Frame: 4 years
|
Amount of time following ABT-199 administration until >25% increase in serum IgM
|
4 years
|
Overall Response Rate Among CXCR4 Mutated Participants
Time Frame: 2 years
|
Overall Response Rate for participants who tested positive for a CXCR4 mutation= Minor response (>25%-50% reduction in serum IgM from baseline) + Partial Response (>50-90% reduction in serum IgM from baseline) + Very Good Partial Response (>90% reduction in serum IgM from baseline) + Complete Response (resolution of all symptoms, normalization of serum IgM with disappearance of IgM paraprotein, resolution of any adenopathy or splenomegaly).
|
2 years
|
Overall Response Rate Among Participants Without CXCR4 Mutations
Time Frame: 2 years
|
Overall Response Rate in participants who tested negative for a CXCR4 mutation= Minor response (>25%-50% reduction in serum IgM from baseline) + Partial Response (>50-90% reduction in serum IgM from baseline) + Very Good Partial Response (>90% reduction in serum IgM from baseline) + Complete Response (resolution of all symptoms, normalization of serum IgM with disappearance of IgM paraprotein, resolution of any adenopathy or splenomegaly).
|
2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jorge J Castillo, MD, Dana-Farber Cancer Institute
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Neoplasms, Plasma Cell
- Waldenstrom Macroglobulinemia
- Antineoplastic Agents
- Venetoclax
Other Study ID Numbers
- 15-491
- A15-751 (Other Identifier: AbbVie Inc)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Waldenstrom Macroglobulinemia
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingWaldenstrom Macroglobulinemia | Recurrent Waldenstrom Macroglobulinemia | Refractory Waldenstrom MacroglobulinemiaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Waldenstrom Macroglobulinemia | Refractory Waldenstrom MacroglobulinemiaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedRecurrent Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Waldenstrom Macroglobulinemia | Refractory Waldenstrom MacroglobulinemiaUnited States
-
BeiGeneRecruitingWaldenstrom Macroglobulinemia | Waldenstrom's Macroglobulinemia Recurrent | Waldenstrom's Macroglobulinemia RefractoryUnited States, Australia, China, Spain, United Kingdom
-
Kosin University Gospel HospitalRecruitingWaldenström's MacroglobulinemiaKorea, Republic of
-
BeiGeneCompletedWaldenström's MacroglobulinemiaUnited States, Spain, Australia, France, United Kingdom, Germany, Netherlands, Czechia, Italy, Poland, Belgium, Greece, Sweden
-
Dana-Farber Cancer InstituteBristol-Myers SquibbActive, not recruitingWaldenstrom's MacroglobulinemiaUnited States
-
Dana-Farber Cancer InstituteJanssen, LPCompletedWaldenström MacroglobulinemiaUnited States
-
Central Hospital, Nancy, FranceCompletedWaldenström MacroglobulinemiaFrance
-
Fondazione Italiana Linfomi ONLUSCompletedWaldenstrom's MacroglobulinemiaItaly
Clinical Trials on ABT199
-
Dana-Farber Cancer InstituteAbbVieRecruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Acute Myeloid Leukemia | Acute Myeloid Leukemia With FLT3/ITD Mutation | Refractory Acute LeukemiaUnited States
-
M.D. Anderson Cancer CenterWithdrawnRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Roswell Park Cancer InstituteAbbVieCompletedCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | PSA Progression | Metastatic Prostate Carcinoma in the Soft Tissue | Castration Levels of Testosterone | Prostate Carcinoma...United States
-
Shanghai Tong Ren HospitalRecruiting
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingChronic Lymphocytic Leukemia | Ibrutinib ResistanceUnited States
-
Kerry RogersJanssen Research & Development, LLCWithdrawnChronic Lymphocytic Leukemia | Loss of Chromosome 17p
-
Steven E. CoutreCompletedRecurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnRefractory Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic LymphomaUnited States
-
Astellas Pharma Global Development, Inc.RecruitingAcute Myeloid Leukemia (AML) | FLT3-mutated Acute Myeloid LeukemiaUnited States